HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Marksans Pharma gets USFDA’s final nod for Benzonatate Capsules
Apr-01-2026

Marksans Pharma has received the final approval for Abbreviated New Drug Application (ANDA) from United States Food and Drug Administration (USFDA) for Benzonatate Capsules USP, 100 mg & 200 mg (Rx).

This product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tessalon Capsules, 100 mg and 200 mg, of Pfizer Inc. Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract, reducing the cough reflex and relieving persistent cough, bronchitis, pneumonia or other lung infections.

Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. 


  RELATED NEWS >>